Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD4CAR |
Synonyms | |
Therapy Description |
CD4CAR is a third-generation chimeric antigen receptor that targets CD4 and contains domains, CD28 and 4-1BB, and the signaling domain, CD3zeta, which potentially enhances immune response and leads to lysis of CD4-expressing tumor cells (PMID: 29348865, PMID: 31413761). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD4CAR | CD4CAR is a third-generation chimeric antigen receptor that targets CD4 and contains domains, CD28 and 4-1BB, and the signaling domain, CD3zeta, which potentially enhances immune response and leads to lysis of CD4-expressing tumor cells (PMID: 29348865, PMID: 31413761). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06197672 | Phase I | CD4CAR | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | Recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT06071624 | Phase I | CD4CAR | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | Recruiting | USA | 0 |